AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AI Briefing

• – AN2 Therapeutics initiates Phase 2 trial of epetraborole for M. abscessus complex lung disease.
• – Epetraborole is an orally administered inhibitor of leucyl-tRNA synthetase (LeuRS) for pulmonary disease treatment.
• – Clinical trial aims to evaluate safety, efficacy and pharmacokinetics of epetraborole.